Skip to content

The study of predicting the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer based on image-pathomics

The study of predicting the efficacy of neoadjuvant chemotherapy in locally advanced gastric cancer based on image-pathomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049321
Enrollment
Unknown
Registered
2021-07-30
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

Case series:PF plan, FLOFOX plan or SOX plan

Sponsors

The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Locally advanced gastric cancer (cT2-4aN0-3M0, American Joint Committee on Cancer's AJCC Cancer Staging Manual), and the pathological type of gastroscopy biopsy is gastric adenocarcinoma, including papillary adenocarcinoma, signet ring cell carcinoma and tubular adenocarcinoma; 2.Aged 18 to 75 years; 3.ECOG score of 0-1; 4.Agree to receive neoadjuvant chemotherapy and surgical treatment; 5.Gastroscopy biopsy before neoadjuvant chemotherapy, and tumor specimens obtained; 6.Routine CT examination before neoadjuvant chemotherapy; 7.All Inspections, treatments and evaluations are all carried out in the two centers where the project is expected to be implemented.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of other malignant tumors; 2.Patients contraindicated to anisodamine (such as glaucoma, prostatic hypertrophy), patients allergic to iodine contrast agents, or pyloric obstruction; 3.Patients with poor CT image quality or small lesions that cannot be delineated; 4.Patients with poor pathological image quality due to H&E staining or WSI scanning process errors; 5.Patients with chemotherapy contraindications, or unable to complete neoadjuvant chemotherapy for various reasons; 6.Patients who refuse radical gastric cancer surgery , Or patients undergoing surgery 1 month after the completion of neoadjuvant chemotherapy; 7.Patients whose tissue samples cannot be evaluated by TRG after surgery.

Design outcomes

Primary

MeasureTime frame
Imaging features;Pathological characteristics;

Countries

China

Contacts

Public ContactLi Zhenhui

The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital)

lizhenhui621@qq.com+86 13698736132

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026